



May 30th, 2024



Company presentation

IntegraGen, part of the OncoDNA Group, the cancer theranostic solution company




IntegraGen story

At a glance

-  **~€11,7 m**
2023 Revenue
-  **~430**
Projects delivered in 2023
-  **140** customers served in 2023
-  **11,860** Samples sequenced in 2023
-  **62,650** Bacteria & virus sequenced in P2M in 2023
-  **42** FTEs

From a biomarker discovery start-up to the French NGS leadership



Key competencies & assets

*Strong & stable
Customer base*

*Leading edge Tech
platform*


*Experienced &
recognized Wet lab
team*



*Sales & BD team
delivering € 10 m +
revenues*

*Bio-Informatics & IT
dev team & portfolio
of SW*

We transform biological samples & clinical info into actionable data



From any sample type, anywhere, for multiple use cases, around a unique and proprietary data management process

* SeqOIA 5 years contract closed as of Feb 2024

IntegraGen Genomic services



Use case

Pharma Industry

- Profiling of patients – inclusion in clinical trials
- Monitoring of patient response / Monitoring of residual disease
- Development of Companion Dx biomarkers

Academic & pre-clinical research

- Fundamental research on specific disease
- Retrospective studies of patient cohorts
- Secondary criteria analysis



Type of analysis

- Sequencing : WES/WGS/WTS; panels, capture
- Sequencing data analysis : Genomic interpretation Software (Mercury, Galileo)
- Methylation analysis
- Expression analysis

Sequencing Services for pharma industry & academics

Historical business since
2006

Services to research
community / France

(end-to-end sequencing and large
and targeted panels for tissue and
liquid biopsies)



Growth potential

Servicing pharma & bio-tech
clinical trials with accredited
central molecular biology
laboratory



Versatile Technology platform in Évry



DNA seq

Whole genome (Human, Murine, eucaryots) **Whole Exome, panels**
Blood, Tissue (Bblood, CfDNA, Tissue frozen or FFPE), metagenome

RNA seq

mRNA (human, blood Frozen tissue)
totRNA (human, blood, Frozen & FFPE tissue)
RNA capture (human, blood, Frozen & FFPE tissue)
3'RNA seq (human, blood, Frozen & FFPE tissue)

Epigenetic - Methyl seq

WGEM (human, blood Frozen tissue, cfDNA)
totRNA (human, blood, frozen tissue)
Methyl capture (human, blood, Frozen & FFPE tissue)
Fragmentomics

Extraction & others

Extraction DNA, RNA (total blood, plasma, Frozen & FFPE tissue, cfDNA, saliva, single cell)
Genotyping (human, blood, frozen tissue)
MethEPIC

Sequencing short read

Novaseq X+ (Illumina) : potential for 10,000 WGS/year (FC25B) or 50,000 / year (next Flowcell 10B)
Novaseq 6000 (Illumina) – back-up

Genotyping

Juno/Biomark (Fluidigm) : potential for 2 m genotyping / year
Juno EP1– back-up

Microarray

Iscan (Illumina) : Potential for 3,000 chips /year

QC

Fragment Analyzer (3) Tape Station (Agilent), Multimodal plate reader (Infinite nano) (Tecan) qPCR systems (3) QS5, StepOne (Qiagen)

Robots & other

Pipeting robots Star & Starlet (Hamilton) Mosquito Sonication platform (Covaris) Thermocyclers (96 & 384) qPCR systems (3) QS5, StepOne (Qiagen)



IntegraGen revenues – 2022/2023

<i>In thousand euros (K€)</i>	2023	2022	Var.%
Sales	12 537	13 167	-5%
other revenues	290	329	-12%
Total revenues	12 827	13 496	-5%
Purchases	-4 211	-5 191	-19%
Payroll	-4 826	-4 551	6%
Other charges and taxes	-3 709	-3 692	0%
Total Charges	-12 746	-13 434	-5%
Gross operating income	81	62	30%
Depreciation and amortization	-198	-202	-2%
Total Operating Expenses	-12 944	-13 635	-5%
Operating Income	-117	-139	-16%
Financial expenses	40	67	-41%
Net income before non recurring items	-77	-72	7%
Net result	-181	-72	153%

2027 perspectives



Bio-Pharma BD

- Ability to attract clinical development projects



Delivery
industrialization

- Continue transformation of academic focused lab into industrial delivery of pharma protocols



GM
improvement

- Drive GM above industry standards



Tech edge
maintenance

- Maintain technology leadership

